Longevity and Metabesity: USA Special Case Study

Coming Soon

Early Bird Discount: until Sat, Aug 31, 2019 12:00 PM
As part of Aging Analytics Agency’s media partnership with Metabesity 2019, interested attendees can get a 20% discount off registration by using the discount code AAAM19.

Longevity and Metabesity: USA Special Case Study” is an open-access analytical report produced by Aging Analytics Agency and Metabesity 2019 to examine the links between metabesity, Longevity and the USA’s current health shortfalls, including low health-adjusted life expectancy (HALE) and the large gap between HALE and life expectancy, despite its extremely high per-capita healthcare expenditures, and to chart policy recommendations to neutralize this vast health vs wealth deficit.

Metabesity denotes the common metabolic roots behind some of the most prevalent and costly degenerative diseases burdening the USA economy today. Much of biological aging, which is the largest risk factor for such diseases, can be considered as a disintegration of normal metabolic functioning and coordination. This means that the most effective and economic approach to healthcare necessarily involves the prevention of costly chronic diseases by intervening upon their shared metabolic roots as early as possible, to prevent rather than to treat. Fortunately, science has made large leaps and bounds in identifying the common metabolic and aging-related roots to the most prevalent and costly diseases afflicting Americans today – and the tools, techniques and technologies capable of intervening at those roots in order to expend healthspan, and to compress the incidence of such diseases into the final years of life.

As the issue of aging population intensifies, sick care will become increasingly expensive and ineffective. The USA needs to rapidly deploy a government-led shift from treatment to prevention, and from prevention to precision health, using deep diagnostics and prognostics in combination with biomarkers of aging, metabesity, health and intervention-effectiveness, to delay the onset of disease with as minimal intervention as possible, as early as possible. Seeking synergies between Longevity research, P4 medicine and Artificial Intelligence has the potential to enable rapid and widespread policy and infrastructural reforms for USA healthcare to quickly boost National Healthy Longevity, but only with sufficient government commitment.

The USA holds the greatest share of the multi-trillion dollar global Longevity economy and the majority share of global Longevity Industry companies and players. It also has one of the highest rates of healthcare expenditure. The USA has all the resources necessary to become a global leader in Longevity, Preventive Medicine and Precision Health, and of National Healthy Longevity, but lacks national prioritization by its federal government, and a strategy to unite the activities of its Longevity Industry, AI, and Preventive Medicine industry ecosystems to work in synergy, rather than in discoordination. The USA’s low HALE and high gap between HALE and LE is not a scientific problem, it is a policy problem.